Surgical options, hematologic evaluation, and pathologic changes in Budd-Chiari syndrome

Am J Surg. 1990 Jan;159(1):41-8; discussion 48-50. doi: 10.1016/s0002-9610(05)80605-1.


This article presents a scheme of management for Budd-Chiari syndrome based on experience with 33 patients. Therapy in acute Budd-Chiari syndrome is dictated by the liver biopsy, with hepatocyte necrosis indicating the need for placement of a decompressive shunt. The type of shunt was determined by intrahepatic vena cava obstruction; a higher morbidity rate was associated with the mesoatrial shunt in 11 patients than with a portacaval shunt in 10 patients. Successful shunt placement allowed stabilization of the liver biopsy and maintenance of good hepatocyte function [galactose elimination capacity (preoperative: 349 +/- 40 mg/minute; 20 months: 344 +/- 60 mg/minute)]. Severe fibrosis and reduced galactose elimination capacity (264 +/- 43 mg/minute) indicated advanced disease--chronic Budd-Chiari syndrome--and were indications for liver transplant. Hematologic evaluation documented a myeloproliferative disorder in 8 of the last 13 patients evaluated; perioperative and late anticoagulation and/or chemotherapy reduced recurrent thrombosis. We conclude that the Budd-Chiari syndrome requires different therapies depending on the stage of disease. If no hepatocyte injury is present on biopsy, therapy may not be needed. Acute, reversible injury can be managed by placement of a decompressive shunt. Irreversible damage requires transplantation. Selection of the right therapy requires a complete evaluation.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Budd-Chiari Syndrome / blood
  • Budd-Chiari Syndrome / pathology
  • Budd-Chiari Syndrome / surgery*
  • Humans
  • Liver / pathology
  • Methods
  • Portasystemic Shunt, Surgical